CN103804382A - Compound for treating eczema and application thereof - Google Patents
Compound for treating eczema and application thereof Download PDFInfo
- Publication number
- CN103804382A CN103804382A CN201210447386.1A CN201210447386A CN103804382A CN 103804382 A CN103804382 A CN 103804382A CN 201210447386 A CN201210447386 A CN 201210447386A CN 103804382 A CN103804382 A CN 103804382A
- Authority
- CN
- China
- Prior art keywords
- compound
- eczema
- treatment
- preparation
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Abstract
The invention discloses a compound, a pharmaceutical composition and new application thereof. The new application refers to application in drugs treating eczema. The compound has a very significant effect in treatment of eczema.
Description
Technical field
The present invention relates to compound and pharmacologically acceptable salt and its analogue of a class treatment eczema, the pharmaceutical composition of being prepared by above-claimed cpd and pharmacologically acceptable salt thereof and its analogue, and described compound or pharmaceutically acceptable salt thereof and the purposes of analogue in the medicine of preparation treatment eczema thereof.
Background technology
Eczema (eczema) is that caused by the inside and outside factor of Various Complex a kind of has polymorphism skin damage and easily have the dermatosis that oozes out tendency.This cause of disease complexity is difficult to determine more, subjective symptoms acute pruritus.The state of an illness easily repeatedly, can be delayed for many years and not heal.
Eczema has ear eczema, Hand and Foot Eczema, eczema mammae, anus eczema of external genitalia, legs eczema etc.Eczema can occur in any position, but take exsertion part and side in the wrong as common; Fash often symmetry distributes.Eczema has a variety of classification, and more common classification is to damage characteristicness by skin to be divided into three kinds of acute, subacute and chronic eczemas.Wherein acute eczema is most grain grain large red papules, papulo-vesicle or blister, still has obvious point-like or strip erosion, sepage, incrustation.Infringement indefinite border.When concurrent infection, can occur that warts, purulence are oozed out and scab bits etc.; Subacute eczema is often dealt with improperly and is delayed to come because of acute phase infringement, and skin damages take red papule, maculopapule or incrustation as main, has minority papulo-vesicle or blister and rotten to the corn sepage concurrently; That chronic eczema has more is acute, subacute eczema is not more transformed repeatedly, and skin damages as dark red or reddish brown color spot or maculopapule, and permelting is closed to thicken and is lichenification, and there is scab etc. on surface, is dispersed in minority papule, maculopapule etc. around.
Treat with ointments such as glucocorticosteroid, zinc oxide, furoic acid momisones clinically, but result for the treatment of is limited, efficient not high.The inventor is surprised to find that some compounds and similar compound or its pharmacologically acceptable salt thereof have an unexpected effect on the medicine of preparation treatment eczema, there is no report for this compounds for treating eczema at present.
Summary of the invention
The invention provides one group of compound and similar compound thereof or its pharmacologically acceptable salt new purposes in the medicine of preparation treatment eczema.
Technical scheme of the present invention is as follows:
The invention provides the one group of compound or pharmaceutically acceptable salt thereof that can treat eczema, and analogue, the structure of described compound is as follows:
Compound (A);
Compound (B);
Compound (C);
Compound (D);
Compound (E);
Above formula compound and analogue thereof or its pharmacologically acceptable salt can be prepared into through topical, the various preparations of gastrointestinal administration or parenteral administration.Described preparation comprises ordinary preparation, controlled release preparation, targeting preparation etc.Described local administration preparation is through the paste of the direct administration of skin, patch, various linimentes etc., and described paste, patch, various linimentes etc. can intension microball preparations, nanometer formulation, Liposomal formulation, dendrimer preparation, polyethyleneglycol modified preparation, aqueogel etc.Described parenteral administration preparation is the formulation of suitable intravenous injection, intramuscular injection, subcutaneous injection, bone marrow injection, transdermal administration, mucosa delivery and inhalation.
The inventor studies discovery: this compounds can greatly be alleviated the symptom of eczema, and from the result of pharmacodynamic experiment, the effect of this compounds exceeds the medicine of current clinical application.Be significant for the misery of removing sufferer.
Embodiment
The present invention's compound used can be purchased, and also can be prepared according to disclosed preparation method, and it does not limit therapeutic domain of the present invention.
Medicine Preparation Example
Compound (A);
Compound (B);
Compound (C);
Compound (D);
Compound (E);
Preparation containing compd A ointment:
1. weigh ethylparoben, essence, hexadecanol, aqueous paraffin wax, glyceryl monostearate, the poly-hydroxyl oxygen ester of stearic acid, glycerine, disodium ethylene diamine tetraacetate, carbomer 950mg altogether;
2. mix to put in pure water and dissolve, and add A50mg, after mixing, make paste;
3. carry out the corresponding inspections such as aseptic, stand-by after meeting the requirements.
Preparation containing compd B ointment:
1. weigh ethylparoben, essence, hexadecanol, aqueous paraffin wax, glyceryl monostearate, the poly-hydroxyl oxygen ester of stearic acid, glycerine, disodium ethylene diamine tetraacetate, carbomer 150mg altogether;
2. mix to put in pure water and dissolve, and add B30mg, after mixing, make paste;
3. carry out the corresponding inspections such as aseptic, stand-by after meeting the requirements.
Preparation containing Compound C ointment:
1. weigh ethylparoben, essence, hexadecanol, aqueous paraffin wax, glyceryl monostearate, the poly-hydroxyl oxygen ester of stearic acid, glycerine, disodium ethylene diamine tetraacetate, carbomer 250mg altogether;
2. mix to put in pure water and dissolve, and add C100mg, after mixing, make paste;
3. carry out the corresponding inspections such as aseptic, stand-by after meeting the requirements.
Preparation containing Compound D ointment:
1. weigh ethylparoben, essence, hexadecanol, aqueous paraffin wax, glyceryl monostearate, the poly-hydroxyl oxygen ester of stearic acid, glycerine, disodium ethylene diamine tetraacetate, carbomer 300mg altogether;
2. mix to put in pure water and dissolve, and add D10mg, after mixing, make paste;
3. carry out the corresponding inspections such as aseptic, stand-by after meeting the requirements.
Preparation containing compd E ointment:
1. weigh ethylparoben, essence, hexadecanol, aqueous paraffin wax, glyceryl monostearate, the poly-hydroxyl oxygen ester of stearic acid, glycerine, disodium ethylene diamine tetraacetate, carbomer 95mg altogether;
2. mix to put in pure water and dissolve, and add E 5mg, after mixing, make paste;
3. carry out the corresponding inspections such as aseptic, stand-by after meeting the requirements.
Effect embodiment:
The therapeutic action of medicine A-E to eczema
1, suppress swelling effect: 80 of rats, be divided at random 8 groups, every group 10, be divided at random 8 groups, normal group, model group, furoic acid momisone group and medicine A-E group, experiment is when daily liquid capacity method, measure the right back sufficient volume of each group of rat with homemade volume determination device, then (the painting dose of medicine A-E group is 25ul to smear medicine to each group, the painting dose of furoic acid momisone group is 30mg/), wherein normal group and model group are smeared distilled water, after 1 hour, the egg white (every injection 0.05ml) of the right back sufficient subcutaneous injection 10% of each group (except normal group).Then measure 1 hour with volumetric method, 2 hours, 4 hours, the right back sufficient volume of 6 hours, right back sufficient volume change value is worth being relatively swelling rate with first initial body machine, the swelling rate after the medication of relatively more each group, the action effect of evaluation medicine A-E.
Table 1 swelling rate test-results (n=10)
| Group | 4 hours swelling rates (%) | 6 hours swelling rates (%) |
| Normal group | 0.0±1.9** | 0.0±2.4** |
| Model group | 54.0±12.3 | 53.2±16.4* |
| Furoic acid momisone group | 49.2±10.3 | 43.1±16.7 |
| Medicine A | 23.2±9.5** | 17.8±13.2** |
| Medicine B | 21.6±8.6** | 15.7±11.9** |
| Medicine C | 19.4±10.9** | 14.2±10.3** |
| Medicine D | 24.5±12.2** | 16.1±139** |
| Medicine E | 22.5±14.4** | 15.9±9.5** |
With relatively * P < 0.05**P < 0.01 of model group
2, itching-relieving action: cavy is divided into 8 groups at random, normal group, model group, furoic acid momisone group and medicine A-E group, 10 every group.Test first 24 hours by each group of Guinea Pig Left dorsal portion unhairing, the about 1cm of area
2, and carry out coating the 1st time, and the painting dose of medicine A-E group is 25ul, the painting dose of furoic acid momisone group is to smear twice 30mg/ every day.Abrade unhairing place, left back instep with flint paper, coating 1 time is coating again after 1 hour then, after administration 3 hours, only smears 0.01% histamine phosphate 0.05mL/ at cavy surface of a wound place, observe 5min, after this use successively the concentration of 0.02%, 0.03%, 0.04% speed increase administration histamine phosphate every 5min, only be 50ul/ at every turn, until occur that cavy later licks left back foot, the cumulative histamine phosphate total amount of giving is itch-threshold, record more each treated animal itch-threshold.
The impact (n=10) of table 2 medicine on guinea pig skin itch due to histamine phosphate
| Group | Itch-threshold (histamine phosphate total amount mg) |
| Normal group | 530.6±28.0** |
| Model group | 110.2±29.6 |
| Furoic acid momisone group | 208.1±49.3* |
| Medicine A | 402.3±49.3** |
| Medicine B | 398.1±38.2** |
| Medicine C | 410.4±45.6** |
| Medicine D | 403.7±50.7** |
| Medicine E | 412.1±39.8** |
With relatively * P < 0.05**P < 0.01 of model group
Comprehensive above-mentioned experimental result is reached a conclusion: compound (A), (B), (C), (D), (E) medicine of preparing all can obviously improve the symptom of eczema, play extraordinary therapeutic action, its result for the treatment of is significantly better than clinical application furoic acid momisone.
Claims (8)
1. a compounds or its pharmacologically acceptable salt, and analogue, the structure of described compound is as follows:
Compound (A);
Compound (B);
Compound (C);
Compound (D);
Compound (E).
2. a pharmaceutical composition, it comprises compound claimed in claim 1 and pharmacologically acceptable salt and its analogue.
3. the pharmaceutical composition of claim 2, described compound and pharmacologically acceptable salt thereof and its analogue are prepared into through topical, the various preparations of gastrointestinal administration or parenteral administration.
4. the pharmaceutical composition of claim 3, the various preparations described in it can be ordinary preparation, controlled release preparation and targeting preparation etc.
5. topical described in claim 3 is the various preparations for the direct administration of skin.
6. compound and pharmacologically acceptable salt thereof and its analogue purposes in the medicine of preparation treatment eczema described in claim 2.
7. the purposes of claim 6, the treatment of described eczema contains the treatment to acute, subacute and chronic eczema.
8. the purposes of claim 6, the treatment of the treatment pointer of described eczema to each position eczemas such as ear eczema, Hand and Foot Eczema, eczema mammae, anus eczema of external genitalia, legs eczemas.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210447386.1A CN103804382A (en) | 2012-11-05 | 2012-11-05 | Compound for treating eczema and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210447386.1A CN103804382A (en) | 2012-11-05 | 2012-11-05 | Compound for treating eczema and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103804382A true CN103804382A (en) | 2014-05-21 |
Family
ID=50701814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210447386.1A Pending CN103804382A (en) | 2012-11-05 | 2012-11-05 | Compound for treating eczema and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103804382A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002096361A2 (en) * | 2001-05-30 | 2002-12-05 | Sugen, Inc. | 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
| WO2005030140A2 (en) * | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and methods of use |
| CN1777590A (en) * | 2003-07-30 | 2006-05-24 | 协和发酵工业株式会社 | Indazole derivatives |
| WO2007124221A1 (en) * | 2006-04-18 | 2007-11-01 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders by using pyrimidinediamine compounds |
| CN101827848A (en) * | 2007-08-08 | 2010-09-08 | 葛兰素史密丝克莱恩有限责任公司 | 2- [ (2-{phenylamino}-1H-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] benzamide derivatives as iIGF-1R inhibitors for the treatment of cancer |
-
2012
- 2012-11-05 CN CN201210447386.1A patent/CN103804382A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002096361A2 (en) * | 2001-05-30 | 2002-12-05 | Sugen, Inc. | 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
| CN1777590A (en) * | 2003-07-30 | 2006-05-24 | 协和发酵工业株式会社 | Indazole derivatives |
| WO2005030140A2 (en) * | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and methods of use |
| WO2007124221A1 (en) * | 2006-04-18 | 2007-11-01 | Rigel Pharmaceuticals, Inc. | Methods of treating cell proliferative disorders by using pyrimidinediamine compounds |
| CN101827848A (en) * | 2007-08-08 | 2010-09-08 | 葛兰素史密丝克莱恩有限责任公司 | 2- [ (2-{phenylamino}-1H-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] benzamide derivatives as iIGF-1R inhibitors for the treatment of cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020202081B2 (en) | Methods and compositions of bile acids and salts for reduction of fat | |
| RU2467759C2 (en) | Composition for local use and its applications | |
| WO2014059880A1 (en) | Method for preparation of pomegranate-peel polyphenol gel used to treat gynecological inflammation | |
| CN108836979A (en) | A kind of preparation method of sodium hyaluronate reparation patch and reparation patch and reparation patch Essence | |
| CN111012737A (en) | Flurbiprofen sodium gel and preparation method thereof | |
| WO2014118040A1 (en) | Extract from indigo tinctoria for the topical treatment and prophylaxis of skin disorders | |
| CN101147735A (en) | Pharmaceutical composition for injection and its medicine box | |
| CN101991585B (en) | Percutaneous absorption film coating agent for treating rheumatoid arthritis and preparation method thereof | |
| CN102526006A (en) | Use of amides of mono and dicarboxylic acids in treatment of renal diseases | |
| CN101744815B (en) | Composite medicament of omeprazole sodium | |
| CN102133175B (en) | Amygdalin gel and preparation method and medicinal application thereof | |
| CN103804382A (en) | Compound for treating eczema and application thereof | |
| CN103804305A (en) | Compound for treating eczema and application thereof | |
| CN103638204B (en) | A kind of Chinese medicine composition for the treatment of eczema | |
| CN104161763B (en) | A kind of pharmaceutical composition is as preparing the application treated in dermatitis and eczema | |
| CN104177612A (en) | New nonlinear polymer and preparation and use thereof | |
| CN105147827B (en) | A kind of antibacterial medicines and preparation method thereof | |
| KR20080097420A (en) | Topical preparation composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases | |
| CN103622953B (en) | Application of alizarin violet in preparing medicine for treating kidney cyst | |
| CN104211950A (en) | Nonlinear polymer and preparation and use thereof | |
| AU2020267170B2 (en) | Methods and formulations using lithium to treat gout inflammatory arthropathy and pain | |
| CN104650343A (en) | Novel non-linear polymer as well as preparation method and application thereof | |
| CN105560248A (en) | Pharmaceutical composition for treating fungal infection and preparing method and application thereof | |
| WO2011152755A1 (en) | Pharmaceutical composition for the treatment of disorders of the lower section of the urogenital system | |
| CN104177610A (en) | Non-linear polymer, and preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140521 |